Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy

Blood (2019) 134 (4): 353–362.

https://doi.org/10.1182/blood-2018-10-879643

Published: 2019

Includes: Supplemental data

Journal Articles

PAX5 P80R mutation identifies a novel subtype of B-cell precursor acute lymphoblastic leukemia with favorable outcome

Blood (2019) 133 (3): 280–284.

https://doi.org/10.1182/blood-2018-10-882142

Published: 2019

Includes: Supplemental data

Journal Articles

Argx-110 Targeting CD70, in Combination with Azacitidine, Shows Favorable Safety Profile and Promising Anti-Leukemia Activity in Newly Diagnosed AML Patients in an Ongoing Phase 1/2 Clinical Trial

Adrian F Ochsenbein, MD, Carsten Riether, PhD, Ulrike Bacher, Rouven Müller, MD, Sabine Höpner, PhD, Yara Banz, Magdalena Hinterbrandner, Msc, Mario Bargetzi, MD, Markus G. Manz, MD, Luc Van Rompaey, PhD, Mahan Moshir, MSc, Tim Delahaye, MSc, Domenica Gandini, MD PhD, Ellen Erzeel, Anna Hultberg, PhD, Samson Fung, MD, Hans De Haard, PhD, Nicolas Leupin, MD, Thomas Pabst, MD PhD

Blood (2018) 132 (Supplement 1): 2680.

https://doi.org/10.1182/blood-2018-99-118302

Published: 2018

Journal Articles

Prospective Long-Term Follow-up after First-Line Subcutaneous Cladribine Treatment in Patients with Hairy Cell Leukemia. a Study of the SAKK (Swiss Group for Clinical Cancer Research)

Rudolf A. Benz, MD, Kornelius Arn, MD, Martin Andres, Thomas Pabst, MD PhD, Urban Novak, Felicitas Hitz, MD, Reinhard Zenhäusern, Yves Chalandon, MD PhD, Ulrich Mey, MD, Sabine Blum, Daniel Rauch, Willy Nettekoven, Nathan Cantoni, MD, Mario Bargetzi, MD, Alix O'Meara, MD, Andreas Lohri, MD, Simona Berardi, PhD BSc, Qiyu Li, Georg Stussi, MD

Blood (2018) 132 (Supplement 1): 2875.

https://doi.org/10.1182/blood-2018-99-114301

Published: 2018

Journal Articles

Improvement of Relative Survival in Elderly Patients with Acute Myeloid Leukemia Emerging from Population-Based Cancer Registries in Switzerland from 2001-2013

Annatina Schnegg-Kaufmann, MD, Anita Feller, Helen Boldomero, Alicia Rovó, MD, Markus G Manz, MD, Michael Gregor, MD, Anna Efthymiou, Mario Bargetzi, MD, Urs Hess, MD, Olivier Spertini, MD, Yves Chalandon, MD PhD, Jakob R. Passweg, MDMS, Georg Stuessi, MD, Volker Arndt, MDMPH, Nicolas Bonadies, MD

Blood (2017) 130 (Supplement 1): 863.

https://doi.org/10.1182/blood.V130.Suppl_1.863.863

Published: 2017

Journal Articles

Melphalan Dose in Myeloma Patients over 65 Years of Age Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation

Guido Ghilardi, MD, Thomas Pabst, MD, Barbara Jeker, MD, Rouven Müller, MD, Anne Cairoli, MD, Antonia Mueller, MD, Mario Bargetzi, MD, Felicitas Hitz, MD, Helen Baldomero, Dominik Heim, MD, Davide Rossi, MD PhD, Michele Ghielmini, MD, Erika Lerch, MD, Urs Schanz, MD, Jakob R. Passweg, MDMS, Georg Stussi, MD, Martina Kleber, MD, Bernhard Gerber

Blood (2017) 130 (Supplement 1): 3297.

https://doi.org/10.1182/blood.V130.Suppl_1.3297.3297

Published: 2017

Journal Articles

Effects of the Sympathicomimetic Agonist Mirabegron on Disease Course, Mutant Allele Burden, Marrow Fibrosis, and Nestin Positive Stem Cell Niche in Patients with JAK2 -Mutated Myeloproliferative Neoplasms. a Prospective Multicenter Phase II Trial SAKK 33/14

Beatrice Drexler, MD, Jakob Passweg, MD, Martin Bigler, Alexandre PA Theocharides, MD, Nathan Cantoni, MD, Peter Keller, MD, Georg Stuessi, MD, Axel Rüfer, MD, Rudolf A. Benz, MD, Geneviève Favre, MD, Alexandar Tzankov, MD, Pontus Lundberg, PhD, Andrea Fuhrer, PhD, Christine Biaggi, Markus G Manz, MD, Mario Bargetzi, MD, Simon Mendez-Ferrer, PhD, Radek C. Skoda, MD

Blood (2016) 128 (22): 3108.

https://doi.org/10.1182/blood.V128.22.3108.3108

Published: 2016

Journal Articles

Multicenter Phase II Trial of Bendamustine, Lenalidomide and Dexamethasone (BRd) As 2 nd -Line Therapy for Multiple Myeloma

Blood (2014) 124 (21): 4779.

https://doi.org/10.1182/blood.V124.21.4779.4779

Published: 2014

Journal Articles

Rituximab Plus Lenalidomide Improves the Complete Remission Rate in Comparison with Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. Primary Endpoint Analysis of the Randomized Phase-2 Trial SAKK 35/10

Blood (2014) 124 (21): 799.

https://doi.org/10.1182/blood.V124.21.799.799

Published: 2014

Journal Articles

Autologous Stem Cell Transplantation For Adult Burkitt Lymphoma In The Rituximab Era: A Retrospective Study Of The Lymphoma Working Party (LWP) Of The European Group For Blood and Marrow Transplantation (EBMT)

Syed Ahmed, MRCP, FRCPath, Ariane Boumendil, PhD, Herve Finel, Anna Sureda, MD, PhD, Harry C. Schouten, MD, PhD, Mohamad Mohty, MD PhD, Guustaaf van Imhoff, Wilfried Schroyens, MD, PhD, Jurgen Finke, Nicolaas PM Schaap, MD, PhD, Ignazio Majolino, Prof, Mario Bargetzi, MD, Enrico Maria Pogliani, MD, Boris Afanasyev, Peter Dreger, MD, Mahmoud D. Aljurf, MD

Blood (2013) 122 (21): 3368.

https://doi.org/10.1182/blood.V122.21.3368.3368

Published: 2013

Journal Articles

Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine

Thomas Pabst, Edo Vellenga, Wim van Putten, Harry C. Schouten, Carlos Graux, Marie-Christiane Vekemans, Bart Biemond, Peter Sonneveld, Jakob Passweg, Leo Verdonck, Marie-Cecile Legdeur, Matthias Theobald, Emanuel Jacky, Mario Bargetzi, Johan Maertens, Gert Jan Ossenkoppele, Bob Löwenberg

Blood (2012) 119 (23): 5367–5373.

https://doi.org/10.1182/blood-2011-11-389841

Published: 2012

Includes: Supplemental data

Journal Articles

Autologous peripheral blood stem cell transplantation for acute myeloid leukemia

Edo Vellenga, Wim van Putten, Gert J. Ossenkoppele, Leo F. Verdonck, Matthias Theobald, Jan J. Cornelissen, Peter C. Huijgens, Johan Maertens, Alois Gratwohl, Ron Schaafsma, Urs Schanz, Carlos Graux, Harry C. Schouten, Augustin Ferrant, Mario Bargetzi, Martin F. Fey, Bob Löwenberg, for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), and Swiss Group for Clinical Cancer Research Collaborative Group (SAKK)

Blood (2011) 118 (23): 6037–6042.

https://doi.org/10.1182/blood-2011-07-370247

Published: 2011

Includes: Supplemental data

Journal Articles

Patterns of Bone Marrow Micro Vessel Morphology in AML and High Risk MDS Predict Treatment Outcome Following Intensive Chemotherapy and Bevacizumab

Alida C. Weidenaar, Arja ter Elst, PhD, Cees AGM van Montfort, PhD, Tiny G.J. Meeuwsen-de Boer, Stefano Rosati, MD, Mario Bargetzi, MD, Carlos Graux, MD, PhD, Alois Gratwohl, MD, PhD, Bob Lowenberg, MD, PhD, Gert Ossenkoppele, MD, PhD, Evelina S. De Bont, MD, PhD

Blood (2011) 118 (21): 1555.

https://doi.org/10.1182/blood.V118.21.1555.1555

Published: 2011

Journal Articles

Survival of Patients Autografted for Chemosensitive Hodgkin Lymphoma After Failure of Upfront BEACOPP Escalated Versus ABVD-Like Regimens

Luciano Wannesson, MD, Mario Bargetzi, MD, Anne Cairoli, MD, Dominik Heim, MD, Urs Hess, MD, Erika Lerch, MD, Thomas Pabst, MD, Christoph Renner, MD, Panagiotis Samaras, MD, Emanuele Zucca, MD

Blood (2011) 118 (21): 3098.

https://doi.org/10.1182/blood.V118.21.3098.3098

Published: 2011

Journal Articles

5-Azacytidine to Treat Acute Myeloid Leukemia In Elderly or Frail Patients: A Phase II Study (SAKK 30/07)

Jakob R. Passweg, MD, MS, Thomas Pabst, Sabine Blum, Mario Bargetzi, Hong Sun, Dominik Heim, MD, Georg Stussi, MD, Michael Gregor, Leda Leoncini, Sandrine Meyer-Monard, MD, Peter Brauchli, Yves Chalandon, MD

Blood (2010) 116 (21): 2181.

https://doi.org/10.1182/blood.V116.21.2181.2181

Published: 2010

Journal Articles

A Multi-Center Phase II Study (SAKK 36/06) of Single Agent Everolimus (RAD001) In Patients with Relapsed or Refractory Mantle Cell Lymphoma.

Christoph Renner, Pier Luigi Zinzani, MD, PhD, Remy Gressin, MD, Dirk Klingbiel, Laurence Favet, Felicitas Hitz, Mario Bargetzi, Walter Mingrone, Giovanni Martinelli, MD, Urs Breitenstein, MD, Krimo Bouabdallah, Christine Biaggi, Sergio Cogliatti, Nicolas Ketterer, MD

Blood (2010) 116 (21): 2803.

https://doi.org/10.1182/blood.V116.21.2803.2803

Published: 2010

Journal Articles

Weekly Treatment with a Combination of Bendamustine and Bortezomib in Relapsed or Refractory Indolent Non-Hodgkin’s Lymphoma: A Single- Center Phase 1/2 Study.

Peter R Moosmann, MD, PhD, Marc Heizmann, MD, Nina Kotrubczik, MD, Mario Bargetzi, MD, Martin Wernli, MD

Blood (2008) 112 (11): 1574.

https://doi.org/10.1182/blood.V112.11.1574.1574

Published: 2008

Journal Articles

A Randomized Study of Daily Versus Weekly Administration of 2-Chlorodeoxyadenosine in Patients with Hairy Cell Leukemia.

Reinhard Zenhausern, MD, Nicolas Leupin, Shu-Fang Hsu Schmitz, Max Solenthaler, Andre Tichelli, Dominik Heim, Urs Hess, Leda Leoncini, Mario Bargetzi, Andreas Tobler

Blood (2007) 110 (11): 1352.

https://doi.org/10.1182/blood.V110.11.1352.1352

Published: 2007

Journal Articles

Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly × 4 schedule

Blood (2004) 103 (12): 4416–4423.

https://doi.org/10.1182/blood-2003-10-3411

Published: 2004

Journal Articles

Reconstitution of dendritic and natural killer–cell subsets after allogeneic stem cell transplantation: effects of endogenous flt3 ligand

Elena Chklovskaia, Pegah Nowbakht, Catherine Nissen, Alois Gratwohl, Mario Bargetzi, Aleksandra Wodnar-Filipowicz

Blood (2004) 103 (10): 3860–3868.

https://doi.org/10.1182/blood-2003-04-1200

Published: 2004

NARROW

Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy

PAX5 P80R mutation identifies a novel subtype of B-cell precursor acute lymphoblastic leukemia with favorable outcome

Argx-110 Targeting CD70, in Combination with Azacitidine, Shows Favorable Safety Profile and Promising Anti-Leukemia Activity in Newly Diagnosed AML Patients in an Ongoing Phase 1/2 Clinical Trial

Prospective Long-Term Follow-up after First-Line Subcutaneous Cladribine Treatment in Patients with Hairy Cell Leukemia. a Study of the SAKK (Swiss Group for Clinical Cancer Research)

Improvement of Relative Survival in Elderly Patients with Acute Myeloid Leukemia Emerging from Population-Based Cancer Registries in Switzerland from 2001-2013

Melphalan Dose in Myeloma Patients over 65 Years of Age Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation

Effects of the Sympathicomimetic Agonist Mirabegron on Disease Course, Mutant Allele Burden, Marrow Fibrosis, and Nestin Positive Stem Cell Niche in Patients with JAK2 -Mutated Myeloproliferative Neoplasms. a Prospective Multicenter Phase II Trial SAKK 33/14

Multicenter Phase II Trial of Bendamustine, Lenalidomide and Dexamethasone (BRd) As 2 nd -Line Therapy for Multiple Myeloma

Rituximab Plus Lenalidomide Improves the Complete Remission Rate in Comparison with Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. Primary Endpoint Analysis of the Randomized Phase-2 Trial SAKK 35/10

Autologous Stem Cell Transplantation For Adult Burkitt Lymphoma In The Rituximab Era: A Retrospective Study Of The Lymphoma Working Party (LWP) Of The European Group For Blood and Marrow Transplantation (EBMT)

Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine

Autologous peripheral blood stem cell transplantation for acute myeloid leukemia

Patterns of Bone Marrow Micro Vessel Morphology in AML and High Risk MDS Predict Treatment Outcome Following Intensive Chemotherapy and Bevacizumab

Survival of Patients Autografted for Chemosensitive Hodgkin Lymphoma After Failure of Upfront BEACOPP Escalated Versus ABVD-Like Regimens

5-Azacytidine to Treat Acute Myeloid Leukemia In Elderly or Frail Patients: A Phase II Study (SAKK 30/07)

A Multi-Center Phase II Study (SAKK 36/06) of Single Agent Everolimus (RAD001) In Patients with Relapsed or Refractory Mantle Cell Lymphoma.

Weekly Treatment with a Combination of Bendamustine and Bortezomib in Relapsed or Refractory Indolent Non-Hodgkin’s Lymphoma: A Single- Center Phase 1/2 Study.

A Randomized Study of Daily Versus Weekly Administration of 2-Chlorodeoxyadenosine in Patients with Hairy Cell Leukemia.

Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly × 4 schedule

Reconstitution of dendritic and natural killer–cell subsets after allogeneic stem cell transplantation: effects of endogenous flt3 ligand

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only